Genzyme's "weak" results bemoaned by analysts
23 April 2009
Christopher Spillane
Please Login to read the full article.
23 April 2009
Christopher Spillane
christopher.spillane@informausa.com
Genzyme's first-quarter revenues fell short of analysts' expectations, despite rising by 4% to $1.15 billion. The firm's key product sales were all below analysts' consensus in a quarter that was peppered with regulatory setbacks for Myozyme (alglucosidase alfa). GAAP net income rose by 35% to $195.5...
Please Login to read the full article.
RELATED CONTENT
ANALYSIS
Other Informa Analysis
COMMENT
Other Informa Comment
EVENTS
Today
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
